Abstract
Introduction
There is no clear consensus regarding the technique of surgical revascularization for moyamoya disease and syndrome (MMD/MMS) in the pediatric population. Previous meta-analyses have attempted to address this gap in literature but with methodological limitations that affect the reliability of their pooled estimates. This meta-analysis aimed to report an accurate and transparent comparison between studies of indirect (IB), direct (DB), and combined bypasses (CB) in pediatric patients with MMD/MMS.
Methods
In accordance with PRISMA guidelines, systematic searches of Medline, Embase, and Cochrane Central were undertaken from database inception to 7 October 2022. Perioperative adverse events were the primary outcome measure. Secondary outcomes were rates of long-term revascularization, stroke recurrence, morbidity, and mortality.
Results
Thirty-seven studies reporting 2460 patients and 4432 hemispheres were included in the meta-analysis. The overall pooled mean age was 8.6 years (95% CI: 7.7; 9.5), and 45.0% were male. Pooled proportions of perioperative adverse events were similar between the DB/CB and IB groups except for wound complication which was higher in the former group (RR = 2.54 (95% CI: 1.82; 3.55)). Proportions of post-surgical Matsushima Grade A/B revascularization favored DB/CB over IB (RR = 1.12 (95% CI 1.02; 1.24)). There was no significant difference in stroke recurrence, morbidity, and mortality. After meta-regression analysis, year of publication and age were significant predictors of outcomes.
Conclusions
IB, DB/CB are relatively effective and safe revascularization options for pediatric MMD/MMS. Low-quality GRADE evidence suggests that DB/CB was associated with better long-term angiographic revascularization outcomes when compared with IB, although this did not translate to long-term stroke and mortality benefits.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00381-023-05868-6.
Keywords: Neurosurgery, Pediatric, Moyamoya disease, Moyamoya syndrome, Bypass, Revascularization
Introduction
Moyamoya disease (MMD) or syndrome (MMS) refers to an abnormal progressive steno-occlusive disorder at the distal internal carotid artery (ICA) [1]. Patients are at high risk for transient ischemic stroke (TIA) or stroke. It is asserted that surgical revascularization provides better outcomes for these patients than medical treatment alone. In pediatric patients, the goal of surgery is to augment cerebral blood flow and reduce the risk of ischemic events [2].
Revascularization techniques can be direct, indirect, or combined. Direct bypass (DB) is accomplished by anastomosing extracranial vessels to intracranial vessels (EC-IC bypass), most often the superficial temporal artery (STA) to the middle cerebral artery (MCA) (STA-MCA bypass) [3, 4]. Indirect bypass (IB) has many variations but is generally accomplished by incorporating well-vascularized tissue usually from external carotid artery sources onto the surface of the brain to promote angiogenesis and neovascularization, rather than by direct anastomosis [5–9]. Unlike DB, IB begins to alter the cerebral blood flow only after angiogenesis has taken place, the timescale for which is unpredictable [3]. A combined bypass (CB) utilizes both techniques simultaneously to maximize the effect of short-term and long-term revascularization [3].
There is currently no definite consensus regarding the technique of surgical revascularization in pediatric MMD/MMS [1, 2]. Existing meta-analyses have elegantly attempted to address this controversy in pediatric patients [10, 11]. However, in these studies, repeated patient populations from the same institutions within overlapping time intervals were included [10, 11]. This methodological flaw overstates sample size and number of events, leading to an artificially exaggerated precision in their pooled estimate [12]. In addition, several included primary studies in these meta-analyses had not distinguished outcomes based on the type of bypass nor specifically for children, and hence it was unclear how these meta-analyses were able to distinguish between the techniques or population. This meta-analysis aimed to mitigate against previous methodological limitations and report an accurate and transparent comparison between studies of IB, DB, and CB in pediatric patients with MMD/MMS.
Methods
This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. The protocol was registered on the PROSPERO international prospective register (CRD42022365524).
Outcomes
The primary outcome included any reported perioperative adverse events within 30 days after bypass surgery. This included wound complications, seizures, cerebrospinal fluid (CSF) leak extra-axial hemorrhage, TIA, stroke, and death.
Secondary outcomes included modified Rankin score (mRS), long-term stroke, mortality risk, and degree of angiographic revascularization at last follow-up. The degree of revascularization was graded according to Matsushima’s classification of the proportion of arterial territory (Grade A > 2/3, Grade B = 1/3 to 2/3, Grade C < 1/3) [3].
When angiographic assessment in the primary studies was graded according to a 3-grade classification (poor, moderate, or good), or 4-grade classification (none, poor, medium, or extensive) [14], we classified “good” and “extensive” as Grade A, “moderate” and “medium” as Grade B, and “poor” or “none” as Grades C.
Search strategy
Searches of three electronic databases were undertaken: Ovid Medline, Ovid Embase, and Cochrane Central Register of Controlled Trials (CENTRAL). Searches were performed in each database from its inception until 7 October 2022. The full search strategy is presented in Supplementary Table 1.
Eligibility criteria
Articles were selected for inclusion if they were a primary interventional or observational study evaluating the effectiveness and safety of revascularization surgeries in pediatric MMD/MMS. The review included studies on exclusively pediatric patients (< 18 years). Studies that had evaluated both pediatric and adult MMD/MMS but reported outcomes specific to the pediatric population were included. Studies that had evaluated various revascularization techniques but reported outcomes specific for the particular technique were included.
The review excluded narrative and systematic reviews, editorials, commentaries, opinion papers, letters, education papers, conference abstracts, protocols, reports, theses, or book chapters as they were unlikely to contain sufficient detail about the effectiveness and safety of both treatments.
Study selection
All titles and abstracts were screened against the pre-defined eligibility criteria developed independently by two reviewers (KSL and JJYZ). A full list of inclusion and exclusion criteria of studies is stated in Supplementary Table 2. Disagreements were resolved by discussion, and where agreement could not be reached, the senior reviewer assisted with decision-making (AHDS). Agreement among the reviewers was evaluated using Cohen’s kappa [15].
The institutions and data collection period were scrutinized to avoid multiple counting. In the event of multiple publications analyzing the same cohort of patients/hemispheres, the publication that reported the largest patient data with the most relevant outcomes was used for evaluation.
Data extraction
A pro forma was developed and piloted to extract data on the following variables to ensure standardization and consistency in this process: (1) study details; (2) study design; (3) participant demographics; (4) country, institution, and data collection period; (5) selection criteria; (6) treatment and control; (7) indication for treatment; and (8) results.
Risk of bias assessment
The quality of included studies was assessed using the Joanna Briggs Institute (JBI) checklist for cohort studies and case series [16]. KSL and JJYZ assessed the quality of all included studies and discussed discrepancies until consensus was reached.
Statistical analysis
Meta-analyses of primary end points were performed assuming the random effects model to account for heterogeneity within and between individual studies [16].
We analyzed both DB and CB as a single cohort compared with IB. The rationale is that in CB, patients undergo a direct and an indirect component of the revascularization in the same setting. The direct component would afford an immediate increase in cerebral perfusion, while the indirect collateralization would take months to a year to form [3]. As reported denominators were heterogenous, analyses by both patients and hemispheres were performed whenever possible. To obtain risk ratios (RRs) from reported binary outcomes between DB/CB and IB, a pairwise meta-analysis was conducted using the Mantel–Haenszel method, using the Paule-Mandel estimator. Overall pooled proportions were computed using the generalized linear mix model (GLMM) [16]. Knapp-Hartung adjustments were used to calculate the 95% confidence intervals (CIs) around the pooled effect to reduce the risk of a Type 1 error.
For the pooling of means of numerical variables, we computed missing means and standard deviations (SDs) from medians, ranges, and interquartile ranges (IQRs) using the methods proposed by Hozo et al. and Wan et al. [17, 18].
The I2 statistic was used to present inter-study heterogeneity, where I2 ≤ 30%, between 30 and 50%, between 50 and 75%, and ≥ 75% were considered to indicate low, moderate, substantial, and considerable heterogeneity, respectively [16]. P values for the I2 statistic were derived from the chi-squared distribution of Cochran’s Q test.
Summary-level meta-regression was performed using the mixed-effects model after computation of the SD of Freeman-Tukey double arcsine transformed proportions, to identify predictors of perioperative TIA, stroke, long-term revascularization, stroke, and mortality. Predictors were year of publication, age, presence of MMS, presence of sickle cell disease (SCD), neurofibromatosis (NF1), and Down syndrome, in accordance with the literature [5, 7, 19, 20]. Summary-level meta-regression was additionally performed using a mixed-effect meta-analysis model by the GLMM method, as a sensitivity analysis to examine the robustness of the former approach.
The publication bias of studies was assessed visually using funnel plots and quantitatively using Egger’s regression test [16]. The GRADE approach was used to evaluate the quality of evidence for each outcome.
All statistical analyses were performed using R software version 4.2.1 (R Foundation for Statistical Computing, 2022), with the package meta. P values less than 0.05 were considered statistically significant.
Results
Study selection and characteristics
As expected, a substantial number of studies were excluded because they had reported data from the same cohort of patients/hemispheres across overlapping time periods. These were commonly from large high-volume institutions such as Beijing Tiantan Hospital [21–25], Boston Children’s Hospital [5–9, 20, 26–30], and Seoul National University Children’s Hospital [31–34]. Consequently, only one publication that reported the largest patient data with the most relevant outcomes was included in our analysis.
Thirty-seven studies met the eligibility criteria for inclusion in our systematic review and meta-analysis (Fig. 1) [2–4, 19, 35–67]. The reliability of the study selection was substantial at both the title and abstract (Cohen’s κ = 0.86) and the full-text review stages (Cohen’s κ = 1.00) [15].
Fig. 1.
PRISMA flow diagram for studies included and excluded
All included studies were retrospective observational studies—eight cohort studies and 29 case series. A total of 37 studies reporting 2460 pediatric patients were included. Only 36 studies had reported the number of hemispheres, and the total hemisphere count was 4432. Thirty-two studies reported outcomes of IB. Of these, 31 studies reported the number of hemispheres in the IB group (3524) and all 34 reported the number of patients (2227). Seventeen studies reported outcomes of DB/CB. All 17 studies reported the number of hemispheres in the DB/CB group (905) whilst only 10 reported the number of patients (358). Eleven studies compared outcomes between the IB and DB/CB groups (Table 1).
Table 1.
Summary of included studies
| First author and year | Country | Study design | Institution | Study period | Total hemispheres/surgeries, n | Total patients, n | Type of revascularization | Etiology, n | Imputed mean age at surgery (SD), year* | Male, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Alamri et al. (2019) [35] | UK | Case series | King’s College Hospital | 2007 to 2015 | 9 | 8 | IB–EDAS | 8 MMMS, 8 SCD | 12.7 (2.6) | 4 (50.0) |
| Araki et al. (2022) [36] | Japan | Cohort study | Nagoya University Graduate School of Medicine | 2005 to 2021 | 39 | 21 | IB–EDMS, DB–STAMCA | 21 MMD | 3.6 (1.1) | NR |
| Bao et al. (2015) [37] | China | Case series | People's Liberation Army (PLA) Hospital | 2002 to 2010 | 512 | 288 | IB–EDAS | 288 MMD | 9.9 (4.9) | 146 (50.7) |
| Blauwblomme et al. (2017) [38] | France | Case series | Necker Hospital | 1999 to 2015 | 108 | 64 | IB–MBH |
32 MMMS, 7 SCD, 7 DS, 8 NF1 |
9.1 (4.1) | 33 (51.6) |
| Chen et al. (2018) [39] | China | Case series | The Third Affiliated Hospital | 2002 to 2015 | 18 | 10 | IB–Pial synangiosis | MMD | 8.5(1.9) | 2 (20.0) |
| Czabanka et al. (2009) [40] | Germany | Case series | Charité-Universitätsmedizin Berlin | NR | 20 | 10 | IB–EMS, DB–STAMCA | MMD | 8.4 (6.4) | 4 (40.0) |
| Darwish et al. (2005) [41] | Australia | Case series | Royal Alexandra Hospital for Children | 1982 to 2004 | 21 | 13 | IB–EDAS, EMS, DB–STAMCA | 4 MMMS, 3 NF1, 1 cranial radiation | 6.1 (3.9) | 5 (38.5) |
| De Oliveira et al. (2009) [42] | Mexico | Case series | Ribeirao Preto Medical School | 2003 to 2008 | 14 | 7 | IB–MBH | 3 MMS, 3DS | 8.4 (3.7) | 2 (28.6) |
| Deng et al. (2021) [43] | China | Cohort study | Beijing Tiantan Hospital | 2010 to 2019 | 533 | 336 | IB–EDAS, MBH, DB–STAMCA | MMD | 9.6 (3.7) | NR |
| Funaki et al. (2014) [44] | Japan | Case series | Kyoto University Graduate School of Medicine | 1978 to 2003 | 114 | 58 | DB–STAMCA | MMD | 6.4 (4.3) | 24 (41.4) |
| Furtado et al. (2021) [45] | India | Case series | MS Ramaiah Medical College and Hospital | 2006 to 2019 | 50 | 28 | IB–EDAS | MMD | NR | NR |
| Gadgil et al. (2018) [46] | USA | Case series | Texas Children’s Hospital | 1997 to 2016 | 169 | 102 | IB–EDAS, dural inversion | 60 MMS, 43 SCD, 5 DS, 1 NF1, 8 cranial radiation, 1 ACTA2 | 10.9 (6.8) | 46 (45.1) |
| Goren et al. (2021) [47] | Israel | Case series | Sheba Medical Center Hospital | 2000 to 2019 | 49 | 27 | IB–EDAS, dural inversion | 5 MMS, 3 DS, 1 NF1, 1 AS | 7.0 (4.7) | 16 (59.3) |
| Griessenauer et al. (2015) [48] | USA | Case series | University of Alabama at Birmingham | 2007 to 2014 | 21 | 14 | IB–EDAS, EMAS | 14 MMMS, 14 SCD | 15.3 (5.3) | 5 (35.7) |
| Guzman et al. (2009) [49] | USA | Cohort study | Stanford University Medical Center | 1991 to 2008 | 168 | 96 | IB–EDAS, EDMS, DB–STAMCA | 16 MMS, 3 DS, 5 NF1, 1 AS | 9.8 (4.9) | NR |
| Ha et al. (2019) [50] | Korea | Case series | Seoul National University Children’s Hospital | 1988 to 2012 | 1283 | 629 | IB–EDAS, MBH | MMMD | 7.7 (4.7) | 303 (48.2) |
| Hall et al. (2016) [51] | USA | Case series | Multi-center – Riley Hospital for Children at Indiana University Health and St. Louis Children’s Hospital/Washington University School of Medicine | 2000 to 2014 | 20 | 12 | IB–EDAS, MBH | 12 MMS, 12 SCD | NR | 8 (66.7) |
| Ishikawa et al. (1997) [52] | Japan | Cohort study | Hokkaido University School of Medicine, Sapporo, Japan | 1988 to 1995 | 64 | 34 | IB–EDAMS, EDAS, DB–STAMCA | MMD | 7.6 (3.6) | 15 (44.1) |
| Isono et al. (2002) [53] | Japan | Case series | Oita Medical University | 1983 | 22 | 11 | IB–EDAMS, EDAS | MMD | 6.3 (2.9) | NR |
| Karasawa et al. (1992) [54] | Japan | Case series | Osaka Neurological Institute | 1974 to 1991 | 196 | 104 | IB–EMS | MMD | NR | NR |
| Kennedy et al. (2014) [19] | USA | Case series | Columbia University Medical Center/Morgan Stanley Children’s Hospital of New York | 1996 to 2012 | 27 | 17 | IB–pial synangiosis | 17 MMS, 17 SCD | NR | 8 (47.1) |
| Kim et al. (2007) [55] | Korea | Cohort study | The Catholic University of Korea College of Medicine, Uijeongbu St. Mary’s Hospital | NR | 36 | 24 | IB–EDAMS, EDAS, STAMCA | MMD | NR | 12 (50.0) |
| King et al. (2010) [56] | Canada | Case series | Hospital for Sick Children | 1996 to 2008 | 18 | 12 | IB–pial synangiosis, MBH | 12 | NR | 13 |
| Kuroda et al. (2010) [57] | Japan | Case series | Hokkaido University Graduate School of Medicine | 1998 to 2009 | 47 | 28 | IB–EDAMS, DB–STAMCA | MMD | 9.8 (3.8) | 7 (25.0)) |
| Matsushima et al. (1998) [3] | Japan | Case series | Kyushu University Graduate School of Medical Sciences | 1983 to 1986 | 72 | 50 | IB–EDAS, EMAS, EMS, DB–STAMCA | MMD | NR | NR |
| Mirone et al. (2019) [58] | Italy | Case series | Santobono- Pausilipon Children’s Hospital | 2007 to 2016 | 14 | 10 | IB–MBH | 6 MMS, 3 NF1, 2 cranial radiation | NR | NR |
| Morshed et al. (2020) [4] | USA | Cohort study | University of California San Francisco | 2006 to 2018 | 49 | 26 | IB–EDAMS, EDAS, EMS, DB–STAMCA | 11 MMD, 1 DS, 4 NF1, 1 cranial radiation, 2 ACTA2 | 8.5 (4.8) | NR |
| Ng et al. (2012) [59] | UK | Case series | Great Ormond Street Hospital | 1996 to 2010 | 134 | 73 | IB–EDMS, EDAS, pial synangiosis, DB–STAMCA | 27 MMS, 13 SCD, 7 DS, 4 NF1, 10 congenital cardiac abnorality,, 2 renal artery stenosis | 8.4 (4.9) | 31 (42.5) |
| Ogiwara and Morota (2012) [60] | Japan | Case series | National Center for Child Health and Development, Tokyo | 2003 to 2010 | 22 | 12 | IB–EDAS, EGS | MMD | 6.4 (2.2) | 7 (58.3) |
| Ong et al. (2020) [61] | Singapore | Case series | Multi-center – KK Women’s and Children’s Hospital and the National University Hospital of Singapore | 2002 to 2019 | 23 | 15 | IB–EDAS, EMAS, pial synangiosis, DB–STAMCA | MMD | 9.4 (4.7) | 5 (33.3) |
| Rashad et al. (2016) [62] | Japan | Case series | Tohoku University Graduate School of Medicine | 2004 to 2015 | 39 | 23 | IB–EDMS, DB–STAMCA | 1 MMMS, 1 NF1 | 9.4 (4.0) | NR |
| Sadashiva et al. (2016) [63] | India | Cohort study | National Institute of Mental Health and Neurosciences | 2006 to 2014 | 85 | 54 | IB–E DAMS, DB–STAMCA | MMMD | 9.0 (4.7) | 25 (46.3) |
| Sakamoto et al. (1997) [64] | Japan | Case series | Oaska City General Hospital | 19 | 10 | IB–EMS, DB–STAMCA | MMD | NR | 0 (0.0) | |
| Scott et al. (2004) [2] | USA | Case series | Boston Children’s Hospital | 1985 to 2001 | 271 | 143 | IB–Pial synangiosis | 77 MMS, 3 SCD, 10 DS, 16 NF1, 15 cranial radiation, 7 congenital cardiac abnorality, 4renal artery stenosis | 7.1 (6.0) | 54 (37.8) |
| Shen et al. (2017) [65] | China | Case series | Fudan | 2011 to 2014 | 134 | 77 | IB–EDMS | 6.5 | 38 | |
| Winstead et al. (2017) [66] | USA | Case series | Children’s Hospital and Research Center Oakland | 2007 | NR | 7 | IB–EDAS | 7 MMS, 7 SCD | NR | 2 (28.6) |
| Yang et al. (2017) [67] | USA | Case series | Johns Hopkins University School of Medicine | 1990 to 2015 | 12 | 7 | IB–EDAMS, EDAS, pial synangiosis | 7 MMS, 7 SCD | 6.9 (4.0) | 4 (57.1) |
AS alagille syndrome, DB direct bypass, DS Down syndrome, EDAS encephaloduroateriosynangiosis, EDAMS encephaloduroarteriomyosynangiosis, EDMS encephaloduromyosynangiosis, EGS encephalogaleosynangiosis, EMAS encephalomyoarteriosynangiosis, EMS encephalomyosynangiosis, IB indirect bypass, MBH multiple burr holes, MMD moyamoya disease, MMS moyamoya syndrome, NF1 neurofibromatosis 1, NR not reported, SCD sickle cell disease, STA-MCA superficial temporal artery to middle cerebral artery bypass, UK United Kingdom, USA United States
*Unless otherwise stated. For pooling of means of numerical variables, we computed missing means and standard deviations (SDs) from medians, ranges (minimum to maximum), and interquartile ranges (IQRs) using the methods proposed by Hozo et al. and Wan et al.
Risk of bias assessment using the JBI checklist for cohort studies and case series are reported in Supplementary Tables S3 and S4.
Baseline characteristics of patients
The gender of the patients was reported in 25 studies in a total of 1731 patients—45.0% male and 55.0% female. The mean and SD of their age were reported or imputable in 29 studies in a total of 2204 patients. Overall pooled mean age was 8.6 years (95% CI: 7.7; 9.5, I2 = 95.3% [p < 0.001]). In total, 308 patients had MMS. The pooled prevalence of MMS within the included population was 21.7% (95% CI: 1.1–86.9%, I2 = 54.2 [p < 0.001]). The number of patients with associated SCD, NF1, Down syndrome, cranial radiation, congenital cardiac abnormality, renal artery stenosis, ACTA2 mutation, and Alagille syndrome were 131 (42.5%), 47 (15.3%), 40 (13.0%), 24 (7.8%), 18 (5.8%), 6 (1.9%), 3 (1.0%), and 3 (1.0%), respectively.
Perioperative adverse events
Table 2 presents a detailed summary of the pooled outcomes in each group and Table 3 presents a direct comparison of outcomes between the two groups. Table 4 summarizes the predictors of these outcomes identified on meta-regression.
Table 2.
Pooled outcomes of included patients/hemispheres between the two groups (indirect bypass and direct/combined bypass)
| Outcomes | Indirect bypass | Direct and combined bypass | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies reporting variable | No. of patients/ hemispheres analyzed | Pooled proportion [95% confidence interval] | I2 (%) | P value of I2 (from χ2 test) | Quality of Evidence (GRADE) | No. of studies reporting variable | No. of patients/ hemispheres analyzed | Pooled proportion [95% confidence interval] | I2 (%) | P value of I2 (from χ2 test) | Quality of Evidence (GRADE) | |
| Perioperative adverse events | ||||||||||||
| Perioperative seizures (hemispheres) | 8 | 2473 | 0.84 [0.16; 4.26] | 79.0 | < 0.001 | Low | 2 | 140 | 0.00 [0.00; 1.00] | 0.0 | 1.000 | Low |
| Perioperative seizures (patients) | 7 | 1060 | 1.32 [0.17; 9.38] | 77.1 | < 0.001 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative subdural hygroma (hemispheres) | 3 | 44 | 4.55 [0.21; 51.74] | 0.0 | 0.993 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative subdural hygroma (patients) | 3 | 32 | 6.25 [0.29; 60.69] | 0.0 | 0.996 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative extra-axial hemorrhage (hemispheres) | 8 | 2592 | 1.53 [0.62; 3.75] | 0.0 | 0.544 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative extra-axial hemorrhage (patients) | 7 | 1126 | 4.09 [2.86; 5.80] | 5.2 | 0.387 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative intracerebral hemorrhage (hemispheres) | 4 | 1326 | 0.36 [0.01; 11.14] | 62.3 | 0.047 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative intracerebral hemorrhage (patients) | 4 | 656 | 0.46 [0.07; 2.82] | 57.4 | 0.070 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative wound complication (hemispheres) | 8 | 810 | 1.18 [0.31; 4.46] | 54.1 | 0.033 | Low | 4 | 177 | 2.26 [0.46; 10.36] | 0.0 | 0.584 | Low |
| Perioperative wound complication (patients) | 6 | 210 | 3.01 [0.61; 13.46] | 41.0 | 0.132 | Low | 2 | 33 | 3.03 [0.00; 99.99] | 0.0 | 1.000 | Low |
| Perioperative CSF leak (hemispheres) | 8 | 1245 | 1.00 [0.34; 2.89] | 30.6 | 0.184 | Low | 2 | 125 | 1.60 [0.00; 99.29] | 0.0 | 0.573 | Low |
| Perioperative CSF leak (patients) | 7 | 459 | 1.72 [0.39; 7.30] | 37.7 | 0.141 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative hydrocephalus requiring shunt (hemispheres) | 2 | 178 | 0.56 [0.00; 99.95] | 0.0 | 1.000 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative hydrocephalus requiring shunt (patients) | 2 | 110 | 0.91 [0.00; 99.97] | 0.0 | 1.000 | Low | NA | NA | NA | NA | NA | NA |
| Perioperative TIA (hemispheres) | 16 | 1782 | 2.62 [1.14; 5.91] | 67.8 | < 0.001 | Low | 6 | 328 | 7.61 [2.20; 23.15] | 78.8 | < 0.001 | Low |
| Perioperative TIA (patients) | 16 | 753 | 4.52 [1.95; 10.09] | 59.1 | < 0.001 | Low | 3 | 106 | 9.74 [0.35; 76.75] | 82.0 | 0.004 | Low |
| Perioperative stroke (hemispheres) | 24 | 3394 | 3.19 [1.91; 5.30] | 54.8 | < 0.001 | Low | 9 | 492 | 4.55 [2.04; 9.84] | 53.1 | 0.030 | Low |
| Perioperative stroke (patients) | 20 | 1506 | 5.94 [3.74; 9.29] | 26.1 | 0.138 | Low | 3 | 89 | 5.62 [0.81; 30.14] | 0.0 | 0.905 | Low |
| Perioperative death (patients) | 20 | 1224 | 0.00 [0.00; 1.00] | 0.0 | 1.000 | Low | 6 | 179 | 0.56 [0.04; 6.89] | 0.0 | 1.000 | Low |
| Outcomes at last follow-up | ||||||||||||
| Revascularization Matsushima Grade A (hemispheres) | 14 | 822 | 56.70 [44.32; 68.29] | 83.4 | < 0.001 | Low | 5 | 284 | 44.40 [5.75; 91.27] | 0.0 | 0.662 | Low |
| Revascularization Matsushima Grades A and B (hemispheres) | 14 | 822 | 85.61 [78.84; 90.48] | 54.3 | 0.008 | Low | 5 | 284 | 95.42 [17.79; 99.95] | 76.8 | 0.002 | Low |
| Stroke recurrence at last follow-up (hemispheres) | 9 | 1599 | 2.34 [0.88; 6.06] | 64.8 | 0.004 | Low | 7 | 411 | 2.38 [0.39; 13.28] | 0.0 | 0.996 | Low |
| Stroke recurrence at last follow-up (patients) | 16 | 1416 | 5.24 [2.97; 9.08] | 54.6 | 0.005 | Low | 6 | 233 | 5.87 [1.41; 21.41] | 0.0 | 0.890 | Low |
| mRS0-1 at last follow-up (patients) | 8 | 604 | 80.38 [68.67; 88.45] | 81.0 | < 0.001 | Low | 4 | 144 | 87.44 [39.85; 98.65] | 0.0 | 0.734 | Low |
| mRS2-3 at last follow-up (patients) | 5 | 481 | 25.28 [3.97; 73.49] | 39.8 | 0.156 | Low | NA | NA | NA | NA | NA | NA |
| Mortality at last follow-up (patients) | 18 | 1454 | 0.30 [0.08; 1.17] | 0.0 | 1.000 | Low | 5 | 210 | 0.48 [0.03; 7.18] | 0.0 | 1.000 | Low |
NA not applicable as fewer than 2 studies reported the outcome by hemisphere/patients
*When the pooled proportions (GLMM method) provided 95% CI of zero to one or nearly one, we advise to interpret with caution as the estimate is likely not reliable
Table 3.
Direct comparison of outcomes between the two groups (indirect bypass and direct/combined bypass with indirect bypass as control)
| Outcomes | No. of studies reporting variable | No. of patients/hemispheres analyzed | Pooled effect size [95% confidence interval] | I2 (%) | P value ofI2 (fromχ2 test) | Quality of Evidence (GRADE) |
|---|---|---|---|---|---|---|
| Perioperative wound complications (hemispheres) | 2 | 582 | RR 2.54 [1.82; 3.55] | 0.0 | 0.978 | Low |
| Perioperative seizures (hemispheres) | 2 | 605 | RR 0.25 [0.00; 2022.04] | 0.0 | 0.514 | |
| Perioperative TIA (hemispheres) | 5 | 935 | RR 0.64 [0.38; 1.10] | 0.0 | 0.786 | Low |
| Perioperative stroke (hemispheres) | 6 | 1056 | RR 1.04 [0.41; 2.65 | 18.9 | 0.290 | Low |
| Total perioperative complications (hemispheres) | 7 | 1056 | RR 1.01 [0.86; 1.17] | 1.2 | 0.415 | Low |
| Perioperative death (hemispheres) | 2 | 1162 | RR 0.72 [0.00; 5682.31] | 0.0 | 0.538 | Low |
| Perioperative death (patients) | 2 | 159 | RR 0.96 [0.04; 22.76] | NA | NA | Low |
| Revascularization Matsushima Grade A (hemispheres) | 3 | 144 | RR 1.56 [0.99; 2.46] | 0.0 | 0.707 | Low |
| Revascularization Matsushima Grades A and B (hemispheres) | 3 | 144 | RR 1.12 [1.02; 1.24] | 0.0 | 0.878 | Low |
Table 4.
Predictors of outcome identified on meta-regression
| Outcome | No. of studies reporting outcome and risk factor | Total no. of patients/hemispheres analyzed | Predictor | P value |
|---|---|---|---|---|
| Indirect | ||||
| Perioperative stroke |
24 24 24 24 24 24 |
3394 3394 3394 3394 3394 3394 |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.128 0.048 0.153 0.221 0.749 0.151 |
| Perioperative TIA |
16 16 16 16 16 16 |
753 753 753 753 753 753 |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.795 0.141 0.867 0.307 0.162 0.133 |
| Revascularisation (Matsushima grades A and B) |
14 14 14 14 14 14 |
822 822 822 822 822 822 |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.464 0.168 0.934 0.873 0.996 0.342 |
| Stroke recurrence |
16 16 16 16 16 16 |
1416 1416 1416 1416 1416 1416 |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.770 0.206 0.608 0.274 0.818 0.751 |
| Mortality |
18 18 18 18 18 18 |
1454 1454 1454 1454 1454 1454 |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.044 0.425 0.071 0.334 0.496 0.372 |
| Direct/combined | ||||
| Perioperative stroke |
9 8 4 NA 4 NA |
492 438 383 NA 383 NA |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.837 0.005 0.558 NA 0.357 NA |
| Perioperative TIA |
6 6 NA NA NA NA |
328 328 NA NA NA NA |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.910 < 0.001 NA NA NA NA |
| Revascularisation (Matsushima grades A and B) |
5 NA NA NA NA NA |
284 NA NA NA NA NA |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.057 NA NA NA NA NA |
| Stroke recurrence |
7 5 NA NA NA NA |
411 196 NA NA NA NA |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.291 0.010 NA NA NA NA |
| Mortality |
5 NA NA NA NA NA |
210 NA NA NA NA NA |
Publication year Age Proportion of MMS Proportion of SCD Proportion of NF1 Proportion of DS |
0.566 NA NA NA NA NA |
NA not applicable as there were too few studies for an accurate meta-regression
Overall pooled rates of perioperative seizures by hemispheres in the IB and DB/CB groups were 0.84% (95% CI: 0.16; 4.26, I2 = 79.0 [p < 0.001]) and 0.00% (95% CI: 0.00; 1.00, I2 = 0.0 [p = 1.000]) respectively. Two studies of 582 hemispheres directly compared rates of perioperative seizures between the two groups. Perioperative seizure rate was comparable between IB and DB/CB (RR = 0.25 (95% CI: 0.00; 2022.03), I2 = 0.0 [p = 0.514]). Overall pooled rates of perioperative wound complications by hemispheres in the IB and DB/CB groups were 1.18% (95% CI: 0.31; 4.46, I2 = 54.1 [p = 0.033]) and 2.26% (95% CI: 0.46; 10.36, I2 = 0.0 [p = 0.584]), respectively. Overall pooled rates of perioperative wound complications by patients in the IB and DB/CB groups were 3.01% (95% CI: 0.61; 13.46, I2 = 41.0 [p = 0.132]) and 3.03% (95% CI: 0.00; 99.99, I2 = 0.0 [p = 1.000]), respectively. Two studies of 582 hemispheres directly compared rates of perioperative wound complications between the two groups. Perioperative wound complications rate was significantly higher in the DB/CB group (RR = 2.54 (95% CI: 1.82; 3.55), I2 = 0.0 [p = 0978]) (Fig. 2a). Overall pooled rates of perioperative CSF leak by hemispheres in the IB and DB/CB groups were 1.00% (95% CI: 0.34; 2.89, I2 = 30.6 [p = 0.184]) and 1.6% (95% CI: 0.00; 99.29, I2 = 0.0 [p = 0.573]), respectively. No direct comparison was available for rates of perioperative CSF leaks.
Fig. 2.
Forest plot comparing rates of a perioperative wound complication, b Matsushima grade A, and c Matsushima grade A/B between DB/CB versus IB
Overall pooled rates of perioperative TIA by hemispheres in the IB and DB/CB groups were 2.62% (95% CI: 1.14; 5.91, I2 = 67.8 [p < 0.001]) and 7.61% (95% CI: 2.20; 23.15, I2 = 78.8 [p < 0.001]), respectively. Pooled rates of perioperative TIA by patients in the IB and DB/CB groups were 4.52% (95% CI: 1.95; 10.09, I2 = 59.1 [p < 0.001]) and 9.74% (95% CI: 0.35; 76.75, I2 = 82.0 [p = 0.004]), respectively. Five studies of 935 hemispheres directly compared rates of perioperative TIA. Perioperative TIA rate was comparable between IB and DB/CB (RR = 0.64 (95% CI: 0.38; 1.10), I2 = 0.0 [p = 0.786]). Pooled rates of perioperative stroke by hemispheres in the IB and DB/CB groups were 3.19% (95% CI: 1.915.30, I2 = 54.8 [p < 0.001]) and 4.55% (95% CI: 2.04; 9.84, I2 = 53.1 [p = 0.030]), respectively. Two studies directly compared rates of perioperative stroke by hemispheres and patients and showed comparability (RR = 0.25 (95% CI: 0.00; 2022.04), I2 = 0.0 [p = 0.514]) and (RR = 0.72 (95% CI: 0.00; 5682.31), I2 = 0.0 [p = 0.538]), respectively. On meta-regression, age significantly predicted rates of perioperative stroke (p = 0.048) in the IB group (Fig. 3a). Further meta-regression demonstrated age further significantly predicted rates of perioperative TIA (p = 0.005) and perioperative stroke (p < 0.001) in the DC/CB group (Fig. 3b and c, respectively).
Fig. 3.
Bubble plot for meta-regression of transformed proportion of a perioperative stroke against age in each IB study, b perioperative stroke against age in each DB/CB study, c perioperative TIA against age in each DB/CB study, d mortality against year of publication in each IB study, and e transformed proportion of long-term stroke recurrence against age in each DB/CB study
Pooled rates of perioperative death in the IB and DB/CB groups were 0.00% (95%CI: 0.00; 1.00, I2 = 0.0 [p = 1.000]) and 0.56% (95%CI: 0.00; 6.89, I2 = 0.0 [p = 1.000]), respectively. Direct comparison between the groups showed comparability (RR = 0.96 (95% CI: 0.04; 22.76), I2 = NA [p = NA]).
Revascularization
Angiographical follow-up duration was reported in 9 studies comprising 1150 hemispheres and pooled duration was 4.3 years (95% CI: 2.2; 6.4, I2 = 99.5 [p < 0.001]).
In the IB group, overall pooled rates of hemispheres with Grade A and Grade A/B revascularization were 56.70% (95% CI: 44.32; 68.29, I2 = 83.4 [p < 0.001]) and 85.61% (95% CI: 78.84; 90.48, I2 = 54.3 [p = 0.008]). In DB/CB group, overall pooled rates of hemispheres with Grade A and Grade A/B revascularization were 44.44% (95% CI: 5.75; 91.27, I2 = 0.0 [p = 0.662]) and 95.42% (95% CI: 17.79; 99.95, I2 = 76.8 [p = 0.002]). Three studies of 144 hemispheres directly compared proportions of Grade A and Grade A/B revascularization. No significant difference in the proportion of Grade A was identified (RR = 1.56 (95% CI 0.99; 2.46), I2 = 0.0 [p = 0.707]), but proportions of Grade A/B favored DB/CB over IB (RR = 1.12 (95% CI 1.02; 1.24), I2 = 0.0 [p = 0.878]) (Fig. 2b and c).
Stroke recurrence, dependence, and mortality at last follow up
Clinical follow-up duration was reported in 33 studies with a total of 1992 patients and pooled duration was 6.5 years (95% CI: 4.4; 8.6, I2 = 99.0 [p < 0.001]).
Overall pooled rates of stroke recurrence by hemispheres at last follow-up in the IB and DB/CB groups were 2.34% (95% CI: 0.88; 6.06, I2 = 64.8 [p = 0.004]) and 2.38% (95% CI: 0.39; 13.28, I2 = 0.0 [p = 0.996]), respectively. Overall pooled rates of stroke recurrence by patients at last follow-up in the IB and DB/CB groups were 5.24% (95% CI: 2.97; 9.08, I2 = 51.6 [p = 0.005]) and 5.87% (95% CI: 1.41; 21.41, I2 = 0.0 [p = 0.890]), respectively. On meta-regression, age (p = 0.010) significantly predicted stroke recurrence in the DC/CB group (Fig. 3e).
Overall pooled rates of patients with mRS scores of 0 and 1 at last follow-up in the IB and DB/CB groups were 80.38% (95% CI: 68.67; 88.45, I2 = 81.0 [p < 0.001]) and 87.44% (95% CI: 39.85; 98.65, I2 = 0.0 [p = 0.734]), respectively. Overall pooled rates of mortality at last follow-up in the IB and DB/CB groups were 0.30% (95% CI: 0.08; 1.17, I2 = 0.0 [p = 1.000]) and 0.48% (95% CI: 0.03; 7.18, I2 = 0.0 [p = 1.000]), respectively. The year of publication (p = 0.044) significantly predicted mortality in the IB group (Fig. 3d).
No direct comparison between the two groups was available for rates of stroke recurrence, dependence, or mortality at last follow-up.
Discussion
Summary of findings
This study represents an accurate systematic review and meta-analysis investigating the role of IB, DB, and CB in pediatric patients with MMD/MMS. Both IB and DB/CB procedures had evidence of efficacy and low rates of complication. A comparative meta-analysis demonstrated a significant benefit in favor of DB/CB in terms of long-term angiographic outcomes, when compared with IB; however, wound complication rates were higher following DB/CB. Other outcomes including perioperative seizures, TIA, stroke, and death were similar between the two groups.
In comparison with the literature
The paucity of studies reporting on DB/CB and widespread available studies investigating IB reflects current patterns of practice favoring IB in the pediatric MMD population. While EDAS and EDAMS were among the originally described techniques for IB, new techniques such as pial synangiosis and multiple burr holes have been added to the surgical armamentarium [38]. Existing evidence is insufficient for there to be consensus regarding the optimal IB technique.
This meta-analysis found low rates of perioperative complications in both DB/CB and IB groups. When compared with IB, CB/DB has been purported to be more technically challenging with a greater risk for postoperative complications [49]. However, many studies have demonstrated the feasibility and safety of DB/CB in pediatric patients with satisfactory outcomes [3, 21, 43, 49]. Factors dissuading the use of DB/CB over IB in the pediatric MMD population, include smaller-caliber recipient and donor vessels, the potential for cross-clamp-induced ischemia, and the risk of poor scalp wound healing. This latter concern was substantiated by the findings of this metanalysis [4, 43]. The lower rates of perioperative adverse events, ranging from wound complications to ischemic events, in our meta-analysis may in general, reflect improved patient selection, anesthetic, and peri-operative care with further knowledge into the management of pediatric MMD/MMS [8]. Regardless of the technique, revascularization should in general be performed in high-volume centers as there is evidence to suggest that caseload correlates with improved care and reduced mortality in pediatric patients with MMD/MMS [68].
In a recent meta-analysis comparing the three bypass techniques in adults, Nguyen et al. [69] found that DB/CB conferred benefits in terms of late stroke recurrence versus IB, with no dissimilarities in terms of perioperative outcomes. Notably, while cerebral hyperperfusion is an undesirable complication of DB in adult patients, this phenomenon is much less frequently observed in pediatric patients and so the conclusions of this study should not constitute a reason to avoid DB in children.
This current metanalysis found evidence of improved angiographic outcomes following DB/CB in comparison with IB; a finding in accordance with previous meta-analyses [70]. Jeon et al. [70] additionally demonstrated a significantly lower risk of future stroke events for DB compared with IB in symptomatic adult patients, although we failed to find evidence of this benefit in our pediatric population.
It has been suggested that patients with various subtypes of MMS undergoing revascularization have poorer outcomes when compared with cases with MMD [5, 7, 19, 20, 59]. Lack of stratification between treatment groups did not allow for a comparison of revascularization strategies between these two pathologies in this current analysis. Furthermore, our meta-regression did not identify the presence of MMS nor its specific phenotypes to significantly affect outcomes; however, this is likely be a function of the limited number of studies reporting them, leading to a Type 2 error. Our meta-regression analysis, however, did identify younger age to be associated with a higher risk of peri-operative stroke and TIA complications. This is consistent with the literature which suggests that younger children with MMD/MMS are thought to be the most severely affected and most challenging to treat [8]. This is likely due to their dynamic clinical course, leading to major strokes on presentation, and poor eventual outcomes [8]. Infants with MMD/MMS have severely compromised cerebrovascular reserve and are particularly vulnerable to anesthetic risks [8].
Clinical implications
As this meta-analysis was not able to directly compare IB and DB/CB for all the stated outcomes, we can at best conclude that both techniques are comparable except for the association of greater rates of angiographic revascularization and wound complication rates in DB/CB. Based on this meta-analysis, it would be prudent to counsel families that although DB/CB is associated of greater rates of angiographic revascularization, this does not necessarily translate into any additional benefit over IB in terms of clinical outcomes such perioperative TIA, perioperative stroke, and long-term stroke recurrence. Indeed, certain studies have suggested a poor correlation between Grades A/B revascularization and future stroke risk [59]. DB/CB allows for immediate augmentation of cerebral blood flow and does not rely on the plasticity and angiogenic potential, unlike IB. In contrast to the immediate flow augmentation by the anastomosis of DB/CB, IB generally relies on the slow neovascularization and recruitment of collaterals over time. In this respect, angiographic success with DB/CB is more reflective of technical anastomosis success. Due to this, the interpretation of angiographic outcomes from IB may be limited if the time to collateral angiogenesis is inadequate, which may explain the findings of our study.
Implication on the direction of future research in MMD/MMS intervention
This systematic review underlines the inconsistency in measurement and reporting within the literature of MMD/MMS. Several included primary studies had not distinguished their outcomes based on the type of bypass, patient population (adult vs pediatric), nor whether or not outcomes were reported in terms of hemispheres or patients. Indeed, previous meta-analyses have also encountered this predicament [10, 11]. This inconsistency in reporting impedes data aggregation and outcome comparison across studies, hindering progress in MMD/MMS management. Conducting a randomized controlled trial in pediatric patients with a rare progressive disease such as MMD/MMS is near impossible due to ethical reasons [1, 2], which highlights the urgency and need for greater standardization in reporting. Consistent reporting in MMD/MMS can be facilitated by an agreed minimum set of indicators to be reported. With a unified standard of data reporting, this will enable valid evidence syntheses and ultimately implementation of management recommendations.
Limitations
Limitations of this meta-analysis include the retrospective and observational nature of included studies. Our study has also highlighted the limited number of studies directly comparing DB/CB and IB for MMD/MMS. This could explain the finding of non-significance in the various outcomes. Additionally, apart from perioperative events, there were no standard time frame with different lengths of clinical follow-up in each study. Furthermore, several outcomes reported in this study have a large encompassing confidence interval, which may be explained by the modest sample size and large heterogeneity between studies. As such, we advise to interpret these outcomes with great caution as the estimates were unlikely to be reliable. Only studies published in English were included; therefore, selection bias may exist because MMD has greater incidence rates among Asian populations. Based on the information from the included studies, our current meta-analysis could not assess whether or not the translation of subjective angiographic assessments across grading scales were accurate in the pediatric cohort. A possible relationship may be uncovered in future with more granular detail. Validation can be achieved by establishing a prospective data registry collected from multiple international centers which can inform future individual participant data meta-analysis in real-world settings. Our meta-analysis included a diverse range of patients of various ethnic diversity, enhancing its external validity. The large number of studies enabled us to perform a meta-regression to explore possible confounders. However, we cannot exclude the possibility that the conclusions drawn in our study may have been affected by residual confounders. Confounders that we did not control for in our analyses include surgeon experience although we controlled for the year of publication given that the surgical and peri-operative management of these patients has generally improved over time due to greater accrued understanding of the condition with time. Most importantly, this meta-analysis is the most reliable and transparent to date as we excluded repeated patient populations from the same institutions within overlapping time intervals.
Conclusions
IB, DB/CB techniques have both been demonstrated to be effective and safe revascularization options for pediatric MMD/MMS. A paucity of cohort studies has a limit direct comparison between these interventions. Available low-quality GRADE evidence suggests that DB/CB is associated with better long-term revascularization outcomes when compared with IB alone, although this did not translate to better long-term stroke outcomes.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
A special thank you to Kenneth Kek Wee Lee (Papa), Lena Lim (Mama), and Chio Tee Koh (Ahma) back home for their unwavering support, without which, I (Keng Siang Lee) would not be able to achieve my educational goals. Love truly overcomes all obstacles (different time zones and distance). I love you all!
Author contribution
All authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publications. Keng Siang Lee: conceptualization, methodology, formal analysis and investigation, writing—original draft preparation, writing—review and editing, visualization, funding acquisition. John J. Y. Zhang: conceptualization, methodology, formal analysis and investigation, writing—review and editing, visualization. Sanjay Bhate: writing—review and editing, supervision. Vijeya Ganesan: writing—review and editing, supervision. Dominic Thompson: conceptualization, writing—review and editing, supervision. Greg James: conceptualization, writing—review and editing, supervision. Adikarige Haritha Dulanka Silva: conceptualization, writing—review and editing, supervision.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Consent for publication
Not applicable.
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Keng Siang Lee and John J. Y. Zhang share co-first authorship.
References
- 1.Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226–1237. doi: 10.1056/NEJMra0804622. [DOI] [PubMed] [Google Scholar]
- 2.Scott RM et al (2004) Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100(2 Suppl Pediatrics):p. 142–9 [DOI] [PubMed]
- 3.Matsushima T et al (1998) Multiple combined indirect procedure for the surgical treatment of children with moyamoya disease. A comparison with single indirect anastomosis and direct anastomosis. Neurosurg Focus 5(5):p. e4 [DOI] [PubMed]
- 4.Morshed RA, et al. Clinical outcomes after revascularization for pediatric moyamoya disease and syndrome: a single-center series. J Clin Neurosci. 2020;79:137–143. doi: 10.1016/j.jocn.2020.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Koss M, et al. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013;11(4):417–425. doi: 10.3171/2012.12.PEDS12281. [DOI] [PubMed] [Google Scholar]
- 6.Karsten MB, Smith ER, Scott RM (2021) Late morbidity and mortality following revascularization surgery for moyamoya disease in the pediatric population. J Neurosurg Pediatr p. 1–6 [DOI] [PubMed]
- 7.Smith ER, et al. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009;26(4):E10. doi: 10.3171/2009.01.FOCUS08307. [DOI] [PubMed] [Google Scholar]
- 8.Jackson EM, et al. Pial synangiosis in patients with moyamoya younger than 2 years of age. J Neurosurg Pediatr. 2014;13(4):420–425. doi: 10.3171/2014.1.PEDS13251. [DOI] [PubMed] [Google Scholar]
- 9.Montaser A et al (2021) Long-term clinical and radiographic outcomes after pial pericranial dural revascularization: a hybrid surgical technique for treatment of anterior cerebral territory ischemia in pediatric moyamoya disease. J Neurosurg Pediatr p. 1–9 [DOI] [PubMed]
- 10.Ravindran K, Wellons JC, Dewan MC. Surgical outcomes for pediatric moyamoya: a systematic review and meta-analysis. J Neurosurg Pediatr. 2019;24(6):663–672. doi: 10.3171/2019.6.PEDS19241. [DOI] [PubMed] [Google Scholar]
- 11.Macyszyn L, et al. Direct versus indirect revascularization procedures for moyamoya disease: a comparative effectiveness study. J Neurosurg. 2017;126(5):1523–1529. doi: 10.3171/2015.8.JNS15504. [DOI] [PubMed] [Google Scholar]
- 12.Lunny C, et al. Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol. 2021;21(1):140. doi: 10.1186/s12874-021-01269-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Czabanka M, et al. Characterization of direct and indirect cerebral revascularization for the treatment of European patients with moyamoya disease. Cerebrovasc Dis. 2011;32(4):361–369. doi: 10.1159/000330351. [DOI] [PubMed] [Google Scholar]
- 15.Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measur. 1960;20(1):37–47. doi: 10.1177/001316446002000104. [DOI] [Google Scholar]
- 16.Lee KS, et al. Tenets for the proper conduct and use of meta-analyses: a practical guide for neurosurgeons. World Neurosurg. 2022;161:291–302.e1. doi: 10.1016/j.wneu.2021.09.034. [DOI] [PubMed] [Google Scholar]
- 17.Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. doi: 10.1186/1471-2288-5-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. doi: 10.1186/1471-2288-14-135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kennedy BC, et al. Pial synangiosis for moyamoya syndrome in children with sickle cell anemia: a comprehensive review of reported cases. Neurosurg Focus. 2014;36(1):E12. doi: 10.3171/2013.10.FOCUS13405. [DOI] [PubMed] [Google Scholar]
- 20.See AP, et al. Down syndrome and moyamoya: clinical presentation and surgical management. J Neurosurg Pediatr. 2015;16(1):58–63. doi: 10.3171/2014.12.PEDS14563. [DOI] [PubMed] [Google Scholar]
- 21.Zhao M, et al. Adolescents with moyamoya disease: clinical features, surgical treatment and long-term outcomes. Acta Neurochir (Wien) 2017;159(11):2071–2080. doi: 10.1007/s00701-017-3286-x. [DOI] [PubMed] [Google Scholar]
- 22.Zhao Y, et al. Comparison of long-term effect between direct and indirect bypass for pediatric ischemic-type moyamoya disease: a propensity score-matched study. Front Neurol. 2019;10:795. doi: 10.3389/fneur.2019.00795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zheng J, et al. Clinical features, surgical treatment, and long-term outcome of a multicenter cohort of pediatric moyamoya. Front Neurol. 2019;10:14. doi: 10.3389/fneur.2019.00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ge P, et al. Clinical features, surgical treatment, and long-term outcome in children with hemorrhagic moyamoya disease. J Stroke Cerebrovasc Dis. 2018;27(6):1517–1523. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.047. [DOI] [PubMed] [Google Scholar]
- 25.Wang C, et al. Encephaloduroarteriosynangiosis for pediatric moyamoya disease: a single-center experience with 67 cases in China. J Child Neurol. 2018;33(14):901–908. doi: 10.1177/0883073818798515. [DOI] [PubMed] [Google Scholar]
- 26.Ahn ES, et al. Chorea in the clinical presentation of moyamoya disease: results of surgical revascularization and a proposed clinicopathological correlation. J Neurosurg Pediatr. 2013;11(3):313–319. doi: 10.3171/2012.11.PEDS12199. [DOI] [PubMed] [Google Scholar]
- 27.Gaillard J, et al. Incidence, clinical features, and treatment of familial moyamoya in pediatric patients: a single-institution series. J Neurosurg Pediatr. 2017;19(5):553–559. doi: 10.3171/2016.12.PEDS16468. [DOI] [PubMed] [Google Scholar]
- 28.Riordan CP et al (2019) Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis. J Neurosurg Pediatr p. 1–7 [DOI] [PubMed]
- 29.Jea A, et al. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics. 2005;116(5):e694–701. doi: 10.1542/peds.2005-0568. [DOI] [PubMed] [Google Scholar]
- 30.Robertson RL, et al. Angiographic changes after pial synangiosis in childhood moyamoya disease. AJNR Am J Neuroradiol. 1997;18(5):837–845. [PMC free article] [PubMed] [Google Scholar]
- 31.Kim SK, et al. Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol. 2010;68(1):92–101. doi: 10.1002/ana.21981. [DOI] [PubMed] [Google Scholar]
- 32.Choi JW, et al. Postoperative symptomatic cerebral infarction in pediatric moyamoya disease: risk factors and clinical outcome. World Neurosurg. 2020;136:e158–e164. doi: 10.1016/j.wneu.2019.12.072. [DOI] [PubMed] [Google Scholar]
- 33.Phi JH, et al. Long-term social outcome in children with moyamoya disease who have reached adulthood. J Neurosurg Pediatr. 2011;8(3):303–309. doi: 10.3171/2011.6.PEDS10578. [DOI] [PubMed] [Google Scholar]
- 34.Kim CY, et al. Encephaloduroarteriosynangiosis with bifrontal encephalogaleo(periosteal)synangiosis in the pediatric moyamoya disease: the surgical technique and its outcomes. Childs Nerv Syst. 2003;19(5–6):316–324. doi: 10.1007/s00381-003-0742-0. [DOI] [PubMed] [Google Scholar]
- 35.Alamri A, et al. Encephaloduroateriosynangiosis (EDAS) in the management of Moyamoya syndrome in children with sickle cell disease. Br J Neurosurg. 2019;33(2):161–164. doi: 10.1080/02688697.2017.1339227. [DOI] [PubMed] [Google Scholar]
- 36.Araki Y, et al. Risk factors for cerebral infarction early after revascularization in children younger than 5 years with moyamoya disease. World Neurosurg. 2022;160:e220–e226. doi: 10.1016/j.wneu.2021.12.115. [DOI] [PubMed] [Google Scholar]
- 37.Bao XY, et al. Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China. Cerebrovasc Dis. 2015;39(2):75–81. doi: 10.1159/000369524. [DOI] [PubMed] [Google Scholar]
- 38.Blauwblomme T, et al. Long-term outcome after multiple burr hole surgery in children with moyamoya angiopathy: a single-center experience in 108 hemispheres. Neurosurgery. 2017;80(6):950–956. doi: 10.1093/neuros/nyw161. [DOI] [PubMed] [Google Scholar]
- 39.Chen C, et al. Surgical revascularization for children with moyamoya disease: a new modification to the pial synangiosis. World Neurosurg. 2018;110:e203–e211. doi: 10.1016/j.wneu.2017.10.137. [DOI] [PubMed] [Google Scholar]
- 40.Czabanka M, et al. Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population. Neurosurg Focus. 2009;26(4):E9. doi: 10.3171/2009.1.FOCUS08298. [DOI] [PubMed] [Google Scholar]
- 41.Darwish B, Besser M. Long term outcome in children with Moyamoya disease: experience with 16 patients. J Clin Neurosci. 2005;12(8):873–877. doi: 10.1016/j.jocn.2004.11.008. [DOI] [PubMed] [Google Scholar]
- 42.Oliveira RS, et al. Effect of multiple cranial burr hole surgery on prevention of recurrent ischemic attacks in children with moyamoya disease. Neuropediatrics. 2009;40(6):260–264. doi: 10.1055/s-0030-1249069. [DOI] [PubMed] [Google Scholar]
- 43.Deng X, et al. Risk factors for postoperative ischemic complications in pediatric moyamoya disease. BMC Neurol. 2021;21(1):229. doi: 10.1186/s12883-021-02283-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Funaki T et al (2014) Incidence of late cerebrovascular events after direct bypass among children with moyamoya disease: a descriptive longitudinal study at a single center. Acta Neurochir (Wien) 156(3):p. 551–9; discussion 559 [DOI] [PubMed]
- 45.Furtado SV, et al. Surgical outcome of encephaloduroarteriomyosynangiosis for moyamoya disease. Neurol India. 2021;69(5):1259–1264. doi: 10.4103/0028-3886.329538. [DOI] [PubMed] [Google Scholar]
- 46.Gadgil N, et al. Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience. J Neurosurg Pediatr. 2018;22(5):541–549. doi: 10.3171/2018.5.PEDS18163. [DOI] [PubMed] [Google Scholar]
- 47.Goren O, et al. Encephaloduroarteriosynangiosis with dural inversion for moyamoya disease in a pediatric and adult population-a single-center 20-year experience. World Neurosurg. 2021;149:e16–e21. doi: 10.1016/j.wneu.2021.02.102. [DOI] [PubMed] [Google Scholar]
- 48.Griessenauer CJ, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16(1):64–73. doi: 10.3171/2014.12.PEDS14522. [DOI] [PubMed] [Google Scholar]
- 49.Guzman R, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease: clinical article. J Neurosurg. 2009;111(5):927–935. doi: 10.3171/2009.4.JNS081649. [DOI] [PubMed] [Google Scholar]
- 50.Ha EJ, et al. Long-term outcomes of indirect bypass for 629 children with moyamoya disease: longitudinal and cross-sectional analysis. Stroke. 2019;50(11):3177–3183. doi: 10.1161/STROKEAHA.119.025609. [DOI] [PubMed] [Google Scholar]
- 51.Hall EM, et al. Reduction in overt and silent stroke recurrence rate following cerebral revascularization surgery in children with sickle cell disease and severe cerebral vasculopathy. Pediatr Blood Cancer. 2016;63(8):1431–1437. doi: 10.1002/pbc.26022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Ishikawa T, et al. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke. 1997;28(6):1170–1173. doi: 10.1161/01.STR.28.6.1170. [DOI] [PubMed] [Google Scholar]
- 53.Isono M, et al. Long-term outcomes of pediatric moyamoya disease treated by encephalo-duro-arterio-synangiosis. Pediatr Neurosurg. 2002;36(1):14–21. doi: 10.1159/000048343. [DOI] [PubMed] [Google Scholar]
- 54.Karasawa J, et al. Long-term follow-up study after extracranial-intracranial bypass surgery for anterior circulation ischemia in childhood moyamoya disease. J Neurosurg. 1992;77(1):84–89. doi: 10.3171/jns.1992.77.1.0084. [DOI] [PubMed] [Google Scholar]
- 55.Kim DS, et al. Surgical results in pediatric moyamoya disease: angiographic revascularization and the clinical results. Clin Neurol Neurosurg. 2007;109(2):125–131. doi: 10.1016/j.clineuro.2006.06.004. [DOI] [PubMed] [Google Scholar]
- 56.King JA, et al. Relative contributions of the middle meningeal artery and superficial temporal artery in revascularization surgery for moyamoya syndrome in children: the results of superselective angiography. J Neurosurg Pediatr. 2010;5(2):184–189. doi: 10.3171/2009.9.PEDS0932. [DOI] [PubMed] [Google Scholar]
- 57.Kuroda S et al (2010) Novel bypass surgery for moyamoya disease using pericranial flap: its impacts on cerebral hemodynamics and long-term outcome. Neurosurgery 66(6):1093–101; discussion 1101 [DOI] [PubMed]
- 58.Mirone G, et al. Multiple burr-hole surgery for the treatment of moyamoya disease and quasi-moyamoya disease in children: preliminary surgical and imaging results. World Neurosurg. 2019;127:e843–e855. doi: 10.1016/j.wneu.2019.03.282. [DOI] [PubMed] [Google Scholar]
- 59.Ng J, et al. Surgical revascularisation for childhood moyamoya. Childs Nerv Syst. 2012;28(7):1041–1048. doi: 10.1007/s00381-012-1743-7. [DOI] [PubMed] [Google Scholar]
- 60.Ogiwara H, Morota N. Bifrontal encephalogaleosynangiosis for children with moyamoya disease. J Neurosurg Pediatr. 2012;10(3):246–251. doi: 10.3171/2012.6.PEDS11483. [DOI] [PubMed] [Google Scholar]
- 61.Ong JA, et al. Revascularisation surgery for paediatric moyamoya disease: The Singapore experience. J Clin Neurosci. 2020;82(Pt B):207–213. doi: 10.1016/j.jocn.2020.11.008. [DOI] [PubMed] [Google Scholar]
- 62.Rashad S, et al. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev. 2016;39(4):615–623. doi: 10.1007/s10143-016-0734-7. [DOI] [PubMed] [Google Scholar]
- 63.Sadashiva N, et al. Moyamoya disease: experience with direct and indirect revascularization in 70 patients from a nonendemic region. Neurol India. 2016;64(Suppl):S78–86. doi: 10.4103/0028-3886.178046. [DOI] [PubMed] [Google Scholar]
- 64.Sakamoto H, et al. Direct extracranial-intracranial bypass for children with moyamoya disease. Clin Neurol Neurosurg. 1997;99(Suppl 2):S128–S133. doi: 10.1016/S0303-8467(97)00071-1. [DOI] [PubMed] [Google Scholar]
- 65.Shen W, et al. Enlarged encephalo-duro-myo-synangiosis treatment for moyamoya disease in young children. World Neurosurg. 2017;106:9–16. doi: 10.1016/j.wneu.2017.06.088. [DOI] [PubMed] [Google Scholar]
- 66.Winstead M, et al. Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: single-institution experience. Pediatr Hematol Oncol. 2017;34(2):100–106. doi: 10.1080/08880018.2017.1313917. [DOI] [PubMed] [Google Scholar]
- 67.Yang W, et al. Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. J Neurosurg Pediatr. 2017;20(3):232–238. doi: 10.3171/2017.1.PEDS16576. [DOI] [PubMed] [Google Scholar]
- 68.Titsworth WL, Scott RM, Smith ER. National analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke. 2016;47(5):1303–1311. doi: 10.1161/STROKEAHA.115.012168. [DOI] [PubMed] [Google Scholar]
- 69.Nguyen VN et al (2022) Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis. Stroke p. 101161STROKEAHA122039584 [DOI] [PubMed]
- 70.Jeon JP, et al. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg. 2018;128(3):793–799. doi: 10.3171/2016.11.JNS161688. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Not applicable.
Not applicable.



